menu
    • menu
    [{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Perceptive Advisors and Cobro Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Financing","leadProduct":"Undisclosed","moa":"Transcription factor","graph1":"Oncology","graph2":"Preclinical","graph3":"C4 Therapeutics","amount2":0.17000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.17000000000000001,"dosageForm":"","sponsorNew":"C4 Therapeutics \/ Perceptive Advisors and Cobro Ventures","highestDevelopmentStatusID":"4","companyTruncated":"C4 Therapeutics \/ Perceptive Advisors and Cobro Ventures"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Termination","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"C4 Therapeutics \/ Roche","highestDevelopmentStatusID":"4","companyTruncated":"C4 Therapeutics \/ Roche"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"CFT8919","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"C4 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"C4 Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"CFT7455","moa":"IKZF1\/3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"C4 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"C4 Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"CFT8634","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"C4 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"C4 Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"CFT7455","moa":"IKZF1\/3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"C4 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"C4 Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"CFT7455","moa":"IKZF1\/3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"C4 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"C4 Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"CFT8634","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"C4 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"C4 Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"CFT1946","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"C4 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"C4 Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"CFT1946","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"C4 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"C4 Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Betta Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"CFT8919","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"C4 Therapeutics","amount2":0.39000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.39000000000000001,"dosageForm":"","sponsorNew":"C4 Therapeutics \/ Betta Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"C4 Therapeutics \/ Betta Pharmaceuticals"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"CFT8919","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"C4 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"C4 Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Degrader-antibody Conjugate","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"C4 Therapeutics","amount2":0.60999999999999999,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.60999999999999999,"dosageForm":"","sponsorNew":"C4 Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"2","companyTruncated":"C4 Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Betta Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Financing","leadProduct":"CFT8919","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"C4 Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"C4 Therapeutics \/ Betta Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"C4 Therapeutics \/ Betta Pharmaceuticals"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"C4 Therapeutics","amount2":0.76000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.76000000000000001,"dosageForm":"","sponsorNew":"C4 Therapeutics \/ Merck KGaA","highestDevelopmentStatusID":"3","companyTruncated":"C4 Therapeutics \/ Merck KGaA"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"CFT7455","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"C4 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"C4 Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Approved","graph3":"C4 Therapeutics","amount2":0.41999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"C4 Therapeutics \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"C4 Therapeutics \/ Biogen"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"CFT8919","moa":"","graph1":"Technology","graph2":"Approved","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"C4 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"C4 Therapeutics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by C4 Therapeutics

    Menu

    C4 Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            C4 Therapeutics

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            C4 Therapeutics

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CFT8919

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial

                            Details : CFT8919 is an orally bioavailable BiDAC™ degrader designed to be potent and selective against EGFR L858R for non-small cell lung cancer patients.

                            Brand Name : CFT8919

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 06, 2024

                            Lead Product(s) : CFT8919

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            C4 Therapeutics

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            C4 Therapeutics

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Discovery

                            Sponsor : Biogen

                            Deal Size : $415.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            C4 Therapeutics Announces Delivery of Second Development Candidate to Biogen

                            Details : The collaboration aims to investigate the use of C4T’s novel protein degradation platform to discover and develop potential new treatments for Alzheimer’s & Parkinson’s disease.

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            September 10, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Discovery

                            Sponsor : Biogen

                            Deal Size : $415.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            C4 Therapeutics

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            C4 Therapeutics

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : Merck Group

                            Deal Size : $756.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            C4 Therapeutics Collaborates with Merck KGaA On Oncogenic Protein Targets

                            Details : The collaboration aims to discover 2 targeted protein degraders against critical oncogenic proteins that C4T has progressed its internal discovery pipeline using its proprietary TORPEDO® platform.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : $16.0 million

                            March 04, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : Merck Group

                            Deal Size : $756.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            C4 Therapeutics

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            C4 Therapeutics

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CFT8919

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Betta Pharmaceuticals

                            Deal Size : $25.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            C4 Therapeutics Closes $25M Investment by Betta Pharmaceuticals

                            Details : The proceeds will be used to develop and commercialize CFT8919, an orally bioavailable BiDAC™ degrader designed to be potent and selective against EGFR L858R for NSCLC patients, in Greater China.

                            Brand Name : CFT8919

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 04, 2024

                            Lead Product(s) : CFT8919

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Betta Pharmaceuticals

                            Deal Size : $25.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            C4 Therapeutics

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            C4 Therapeutics

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Degrader-antibody Conjugate

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Merck & Co

                            Deal Size : $610.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antib...

                            Details : Under the agreement, Merck will develop degrader-antibody conjugates (DACs), an emerging modality designed to selectively target and neutralize disease-causing proteins in cancer cells.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : $10.0 million

                            December 12, 2023

                            Lead Product(s) : Degrader-antibody Conjugate

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Merck & Co

                            Deal Size : $610.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            C4 Therapeutics

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            C4 Therapeutics

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CFT7455,Dexamethasone

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma

                            Details : CFT7455 is an orally bioavailable MonoDAC degrader designed to be highly potent and selective against its intended targets of IKZF1 and IKZF3 and overcome shortcomings of currently approved therapies to treat multiple myeloma (MM) and non-Hodgkin’s lym...

                            Brand Name : CFT7455

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 12, 2023

                            Lead Product(s) : CFT7455,Dexamethasone

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            C4 Therapeutics

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            C4 Therapeutics

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CFT8919

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT8919, an Orally Bioavai...

                            Details : CFT8919 is an orally bioavailable allosteric BiDAC™ degrader that is designed to be potent and selective against EGFR bearing an oncogenic L858R mutation. In preclinical studies, CFT8919 is active in in vitro and in vivo models of L858R driven non-smal...

                            Brand Name : CFT8919

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 05, 2023

                            Lead Product(s) : CFT8919

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            C4 Therapeutics

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            C4 Therapeutics

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CFT8919

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Betta Pharmaceuticals

                            Deal Size : $392 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Comme...

                            Details : Under the terms of the agreement, Betta Pharmaceuticals will develop and commercialize CFT8919, an orally bioavailable BiDAC™ degrader designed to be potent and selective against EGFR L858R for non-small cell lung cancer patients, in Greater China.

                            Brand Name : CFT8919

                            Molecule Type : Small molecule

                            Upfront Cash : $10 million

                            May 30, 2023

                            Lead Product(s) : CFT8919

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Betta Pharmaceuticals

                            Deal Size : $392 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            C4 Therapeutics

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            C4 Therapeutics

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CFT1946,Trametinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT1946, an Orally Bioava...

                            Details : CFT1946 is an orally bioavailable BiDAC™ degrader designed to be potent and selective against BRAF V600 mutant targets. C4T is advancing CFT1946 to the clinic to study treatment for BRAF V600 mutant solid tumors including NSCLC, colorectal cancer, and ...

                            Brand Name : CFT1946

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 30, 2023

                            Lead Product(s) : CFT1946,Trametinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            C4 Therapeutics

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            C4 Therapeutics

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CFT1946

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            C4 Therapeutics Receives Study May Proceed Letter from U.S. FDA to Initiate Phase 1/2 Clinical Trial of CFT194...

                            Details : In pre-clinical studies, CFT1946 is active in vivo and in vitro in models with BRAF-V600E-driven disease and in the escape mutant BRAF models. C4T is advancing CFT1946 to the clinic to study treatment for BRAF-V600 mutant solid tumors including lung, col...

                            Brand Name : CFT1946

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 29, 2022

                            Lead Product(s) : CFT1946

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth